Drugs / CEP-37440
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01922752 | Jul 2013 → Sep 2015 | cancer | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEP-37440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01922752 ↗ |
| Known as | Alk-fak inhibitor cep-37440 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3951811 ↗ |
| Action | Inhibit | “ALK tyrosine kinase receptor inhibitor” CHEMBL3951811 ↗1“Focal adhesion kinase 1 inhibitor” CHEMBL3951811 ↗ |
| Modality | Small molecule | — CHEMBL3951811 ↗ |
| Route | Oral | “CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.” NCT01922752 ↗ |
| Target | ALK | “ALK tyrosine kinase receptor inhibitor” CHEMBL3951811 ↗ |
| Target | PTK2 | “Focal adhesion kinase 1 inhibitor” CHEMBL3951811 ↗ |